NCT04080024已完成1 期
A First-in-human Clinical Evaluation of the Novel Intravenous Contrast Agent SN132D in Patients With Breast and Pancreatic Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 2
- 主要终点
- Number of treatment related adverse events (AEs)
研究概览
简要总结
This phase I, first-in-human (FIH) study is open-label, non-randomised and non-placebo-controlled. The study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of a single intravenous dose of SN132D in approximately 24 patients with breast and pancreatic cancer. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent including willingness to undertake 3 MRI investigations (30 minute each) in one day
- •Histological or cytological diagnosis of breast cancer > 5 mm (cT1c-cT4; cN0-cN3; Mx) or known or suspected pancreatic cancer with hepatic involvement with available or scheduled gadolinium enhanced MRI of the pancreas
- •At least 3 weeks between core needle biopsy and planned pre-dose MRI. Fine needle aspiration is allowed at any time before MRI.
- •Female and at least 18 years of age when signing the informed consent.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 at screening
- •Adequate renal and hepatic function: estimated glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73 m2 (determined by the revised Lund-Malmö GFR estimating equation), bilirubin <1 x upper limit of normal (ULN; (in subjects with liver metastases <5 x ULN)), creatinine <1 x ULN, aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) < 1 x ULN.
- •Bilirubin ULN: 25 µmol/L, creatinine ULN: 90 µmol/L, ASAT ULN: 0.60 µkat/L and ALAT ULN: 0.75 µkat/L) at the screening visit.
- •Females of child-bearing potential* must agree to the use of effective contraception** or practice abstinence during the study and for 30 days after the IMP administration.
- •Adequate haematological function: haemoglobin ≥90 g/L, absolute neutrophil count (ANC) ≥1.3x109 /L and platelet count ≥ 100 x 109 /L.
- •A female of child-bearing potential is a sexually mature female who 1) has not undergone a hysterectomy or bilateral oophorectomy, or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e. had had menses at any time in the preceding 24 consecutive months).
- •Effective contraception is defined as contraceptive methods with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD]or intrauterine hormone-releasing system [IUS]).
排除标准
- •Female patients who are pregnant or who are currently breast feeding.
- •Conditions contraindicating MRI including, but not limited to, body mass index (BMI) > 40 kg/m2 at screening claustrophobia, metallic implants or internal electrical devices (e.g., cochlear implant, nerve stimulator, gastric pacemaker, bladder stimulator, pacemaker, defibrillator, artificial valves in heart, aneurysm clips, etc.), and permanent makeup or tattoos which in the Investigator's opinion might jeopardise the patient's safety or interfere with the imaging measurements. The Investigator is encouraged to contact the MR clinic for advice on which implants, tattoos, etc may be unsuitable.
- •Other malignancy than breast and pancreatic cancer within the past 5 years with the exception of in situ removal of basal cell carcinoma or resected benign colonic polyps.
- •Moderate to severe hypertension as judged by the Investigator.
- •History of significant cardiovascular disease such as myocardial infarction, congestive heart failure, stroke, serious cardiac arrhythmias. History of angina within 6 months prior to screening.
- •Clinically diagnosed obstruction of bile duct as judged by investigator.
- •Prolonged QTcF (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting electrocardiogram (ECG) at the time of screening, as judged by the Investigator.
- •Abnormalities detected during examination at screening and admission, which in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.
- •Active infection requiring systemic treatment within one week prior to agent administration.
- •History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study.
- •Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibodies.
- •Any use of alcohol within 24 hours of admission to the clinic.
- •Plasma donation within 1 month of screening or any blood donation or corresponding blood loss during 3 months prior to screening.
- •Use of investigational agent within four weeks before Visit 1 or plans to initiate treatment with an investigational agent during the study.
研究组 & 干预措施
Single dose (i.v.) SN132D
Experimental
干预措施: SN132D (Drug)
结局指标
主要结局
Number of treatment related adverse events (AEs)
时间窗: Baseline up to 2 weeks
Frequency, severity and seriousness of AEs including clinically significant changes in physical examinations, safety laboratory parameters, vital signs, electrocardiograms and injection site reactions will be assessed.
次要结局
- Pharmacokinetics as measured by area under the plasma concentration-time curve from time 0 extrapolated to infinite time (AUCinf) for Mn (mM x min)(Baseline up to Day 2)
- Pharmacokinetics as measured by maximum plasma concentration (Cmax) for Mn (µg Mn/mL)(Baseline up to Day 2)
- Preliminary efficacy (MRI enhancing effect)(Day 1)
- Pharmacokinetics as measured by plasma elimination half-life (T½) for Mn (h)(Baseline up to Day 2)
- Pharmacokinetics as measured by total body clearance (CL) for Mn (L/h)(Baseline up to Day 2)
- Pharmacokinetics as measured by time to Cmax (Tmax) for Mn (h)(Baseline up to Day 2)
- Pharmacokinetics as measured by apparent volume of distribution at steady state (Vss) for Mn (L) the terminal phase half-life (T½) for manganese (Mn)(Baseline up to Day 2)
- Pharmacokinetics as measured by area under the plasma concentration-time curve from time 0 to the last measurable time point (AUC0-t) for manganese (Mn) (mM x min)(Baseline up to Day 2)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A First-In-Human Trial of pTTL in Advanced Colorectal CancerColorectal CancerNCT05908643Neogap Therapeutics AB16
撤回
1 期
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT05266950Beijing Boren Hospital7
撤回
1 期
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/LymphomaT-Cell Acute Lymphoblastic Leukemia/LymphomaNCT05487495Beijing Boren Hospital18
终止
1 期
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic LeukemiaT-Cell Acute Lymphoblastic LeukemiaNCT05032599Beijing Boren Hospital19
尚未招募
1 期
A Phase 1, Open Label, First in Human (FIH) Study Investigating Photodynamic Therapy (PDT) with INV043 0.5% Ointment in Adults with Non-melanoma Skin Cancerson melanoma skin cancerNon melanoma skin cancerCancer - Non melanoma skin cancerACTRN12624000310561Invion Limited150